Megan Sniecinski
Known title: Chief Operating OfficerCIK: 0001781480
Associated companies
Transaction History
| PRAX | ▲ Buy | Grant | 89 | $15K | 5/14/2026 | View on chart |
| PRAX | ▼ Sell | Tax Withholding | 885 | $244K | 1/12/2026 | View on chart |
| PRAX | ▼ Sell | Tax Withholding | 1,087 | $314K | 1/10/2026 | View on chart |
| PRAX | ▲ Buy | Grant | 9,625 | $0 | 1/8/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Praxis Precision Announces Inducement Grants Under Nasdaq Rule
Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.
Praxis Precision Announces Inducement Grants Under Nasdaq Rule. Praxis Precision Medicines disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4). This move is a compliance measure aimed at meeting Nasdaq’s shareholder requirements and may affect the company’s share structure. The announcement is a routine regulatory update rather than a new product or earnings event.